Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MMP2 | P08253 | 2/20 | 0.50 |
| ▸ | MMP9 | P14780 | 2/20 | 0.50 |
| ▸ | HTT | P42858 | 6/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.48 |
| ▸ | CA1 | P00915 | 2/20 | 0.45 |
| ▸ | CA2 | P00918 | 2/20 | 0.45 |
| ▸ | CA9 | Q16790 | 1/20 | 0.45 |
| ▸ | SMN1; SMN2 | Q16637 | 7/20 | 0.44 |
| ▸ | LMNA | P02545 | 5/20 | 0.44 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.44 |
| ▸ | NPC1 | O15118 | 2/20 | 0.44 |
| ▸ | RAB9A | P51151 | 2/20 | 0.44 |
| ▸ | TP53 | P04637 | 1/20 | 0.44 |
| ▸ | MAPT | P10636 | 1/20 | 0.44 |
| ▸ | TSHR | P16473 | 1/20 | 0.44 |
| ▸ | XBP1 | P17861 | 1/20 | 0.44 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.44 |
| ▸ | MDM2 | Q00987 | 1/20 | 0.44 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.43 |
| ▸ | SOS1 | Q07889 | 3/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9720036 | 0.89 | HTT (0.58) | HTTALDH1A1SMN1; SMN2LMNAHSD17B10 | |
| SCHEMBL433497 | 0.89 | HTT (0.58) | HTTALDH1A1SMN1; SMN2LMNAHSD17B10 | |
| SCHEMBL155902 | 0.87 | ALDH1A1 (0.55) | MMP2MMP9ALDH1A1CA1CA2 | |
| SCHEMBL3669592 | 0.83 | HTT (0.55) | MMP2MMP9HTTALDH1A1CA1 | |
| SCHEMBL1133769 | 0.81 | PGR (0.53) | MMP2MMP9HTTALDH1A1CA1 | |
| SCHEMBL9536733 | 0.81 | SOS1 (0.64) | MMP2MMP9HTTALDH1A1CA1 | |
| SCHEMBL31244 | 0.81 | SOS1 (0.64) | MMP2MMP9HTTALDH1A1CA1 | |
| SCHEMBL282256 | 0.79 | SOS1 (0.66) | MMP2MMP9HTTALDH1A1CA1 | |
| SCHEMBL1133721 | 0.79 | HTT (0.50) | MMP2MMP9HTTALDH1A1CA1 | |
| SCHEMBL3913682 | 0.79 | HTT (0.48) | HTTALDH1A1SMN1; SMN2LMNAHSD17B10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8524194-B2 | Radiolabelled MMP selective compounds | ACADEMISCH MEDISCH CENTRUM BIJ DE UNIVERSITEIT VAN AMSTERDAM (NL) | 2013-09-03 | — | — | US | disclosed |
| US-20110171133-A1 | RADIOLABELLED MMP SELECTIVE COMPOUNDS | VERENIGING VOOR CHRISTELIJK HOGER ONDERWIJS, WETENSCHAPPELIJK ONDERZOEK EN PATIENTENZORG (NL) | 2011-07-14 | — | — | US | disclosed |
| EP-2285759-A1 | RADIOLABELLED MMP SELECTIVE COMPOUNDS | Academisch Medisch Centrum bij de Universiteit van Amsterdam (NL) | 2011-02-23 | — | — | EP | disclosed |
| WO-2009139633-A1 | RADIOLABELLED MMP SELECTIVE COMPOUNDS | ACADEMISCH MEDISCH CENTRUM BIJ DE UNIVERSITEIT VAN AMSTERDAM (NL) | 2009-11-19 | — | — | WO | disclosed |
| WO-2009139634-A1 | RADIOLABELLED MMP SELECTIVE COMPOUNDS | ACADEMISCH MEDISCH CENTRUM BIJ DE UNIVERSITEIT VAN AMSTERDAM (NL) | 2009-11-19 | — | — | WO | disclosed |
| EP-2119690-A1 | Radiolabelled MMP selective compounds | Academisch Medisch Centrum bij de Universiteit van Amsterdam (NL) | 2009-11-18 | — | — | EP | disclosed |
| US-H1992-H1 | INHIBITION OF METALLOPROTEINASES AND TUMOR NECROSIS FACTOR CONVERTASE WHICH DEGRADE PROTEIN COMPONENTS OF EXTRACELLULAR MATRIX | AGOURON PHARMACEUTICALS, INC. | 2001-09-04 | — | — | US | disclosed |
| EP-0973748-A1 | METALLOPROTEINASE INHIBITORS, PHARMACEUTICAL COMPOSITIONS CONTAINING THEM AND THEIR PHARMACEUTICAL USES | AGOURON PHARMACEUTICALS, INC. (US) | 2000-01-26 | — | — | EP | disclosed |
| US-5985900-A | TREATING TUMOR GROWTH, INVASION OR METASTASIS, OSTEOARTHRITIS, RHEUMATOID ARTHRITIS, OSTEOPOROSIS, PERIODONTITIS, GINGIVITIS, CHRONIC DERMAL WOUNDS, CORNEAL ULCERATION, DEGENERATIVE SKIN DISORDERS, MULTIPLE SCLEROSIS, STROKE, ATHEROSCLEROSIS, | AGOURON PHARMACEUTICALS, INC. (US) | 1999-11-16 | — | — | US | disclosed |
| WO-1998050348-A1 | METALLOPROTEINASE INHIBITORS, PHARMACEUTICAL COMPOSITIONS CONTAINING THEM AND THEIR PHARMACEUTICAL USES | AGOURON PHARMACEUTICALS, INC. (US) | 1998-11-12 | — | — | WO | disclosed |
| WO-1998043963-A1 | METALLOPROTEINASE INHIBITORS, PHARMACEUTICAL COMPOSITIONS CONTAINING THEM AND THEIR PHARMACEUTICAL USES | AGOURON PHARMACEUTICALS, INC. (US) | 1998-10-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110171133-A1 | RADIOLABELLED MMP SELECTIVE COMPOUNDS | MMP1, MMP3, MMP9 | MMP2 4/4885MMP9 3/4885HTT 3092/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.